Medicines planning
46 results
Applied filters
Understanding biological and biosimilar medicines
1 August 2025Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions
Preparing to use denosumab 120mg biosimilar
1 October 2026Biosimilars of denosumab 120mg (Xgeva) are available. We offer general information and implementation advice.
Preparing to use denosumab 60mg biosimilar
1 October 2026Biosimilars of denosumab 60mg (Prolia) are available. We offer general information and implementation advice.
Preparing to use omalizumab biosimilar
20 July 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. We offer general information and implementation advice.
The licence and supporting evidence for omalizumab biosimilar
20 July 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. Review its indications, evidence, and main differences.
The licence and supporting evidence for aflibercept biosimilars
4 February 2026Aflibercept 2mg biosimilars are available for NHS use. Learn about supporting evidence and differences.
The licence and supporting evidence for ranibizumab biosimilars
5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Preparing to use ranibizumab biosimilar
5 November 2025Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
The licence and supporting evidence for denosumab 60mg biosimilars
24 April 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for golimumab biosimilar
2 June 2026We highlight evidence for available golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).